WO2000001345A3 - Utilisation d'un compose amphipathique pour adjuver un vaccin sous-unitaire - Google Patents

Utilisation d'un compose amphipathique pour adjuver un vaccin sous-unitaire Download PDF

Info

Publication number
WO2000001345A3
WO2000001345A3 PCT/FR1999/001604 FR9901604W WO0001345A3 WO 2000001345 A3 WO2000001345 A3 WO 2000001345A3 FR 9901604 W FR9901604 W FR 9901604W WO 0001345 A3 WO0001345 A3 WO 0001345A3
Authority
WO
WIPO (PCT)
Prior art keywords
adjuvant
providing
amphipathic compound
subunit vaccine
compound
Prior art date
Application number
PCT/FR1999/001604
Other languages
English (en)
Other versions
WO2000001345A2 (fr
Inventor
Anne Darbouret
Florence Brunel
Jorge Ronco
Original Assignee
Pasteur Merieux Serums Vacc
Anne Darbouret
Florence Brunel
Jorge Ronco
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Merieux Serums Vacc, Anne Darbouret, Florence Brunel, Jorge Ronco filed Critical Pasteur Merieux Serums Vacc
Priority to EP99929389A priority Critical patent/EP1093382A2/fr
Priority to CA 2337048 priority patent/CA2337048A1/fr
Priority to AU46217/99A priority patent/AU4621799A/en
Priority to US09/720,863 priority patent/US6472159B1/en
Publication of WO2000001345A2 publication Critical patent/WO2000001345A2/fr
Publication of WO2000001345A3 publication Critical patent/WO2000001345A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention a pour objet l'utilisation d'un composé amphipathique pour la préparation d'une composition vaccinale comprenant au moins un antigène sous-unitaire destinée à être administrée à des populations-cibles comprenant des individus 'Non-Répondeurs' audit antigène. Un composé amphipathique particulier est le DC-chol.
PCT/FR1999/001604 1998-07-03 1999-07-02 Utilisation d'un compose amphipathique pour adjuver un vaccin sous-unitaire WO2000001345A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP99929389A EP1093382A2 (fr) 1998-07-03 1999-07-02 Utilisation d'un compose amphipathique pour adjuver un vaccin sous-unitaire
CA 2337048 CA2337048A1 (fr) 1998-07-03 1999-07-02 Utilisation d'un compose amphipathique pour adjuver un vaccin sous-unitaire
AU46217/99A AU4621799A (en) 1998-07-03 1999-07-02 Use of an amphipathic compound for providing an adjuvant to subunit vaccine
US09/720,863 US6472159B1 (en) 1998-07-03 1999-07-02 Use of an amphipathic compound for providing an adjuvant to a subunit vaccine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR98/08700 1998-07-03
FR9808700A FR2781160B1 (fr) 1998-07-03 1998-07-03 Utilisation d'un compose amphipathique pour adjuver un vaccin sous-unitaire

Publications (2)

Publication Number Publication Date
WO2000001345A2 WO2000001345A2 (fr) 2000-01-13
WO2000001345A3 true WO2000001345A3 (fr) 2000-02-24

Family

ID=9528373

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR1999/001604 WO2000001345A2 (fr) 1998-07-03 1999-07-02 Utilisation d'un compose amphipathique pour adjuver un vaccin sous-unitaire

Country Status (6)

Country Link
US (1) US6472159B1 (fr)
EP (1) EP1093382A2 (fr)
AU (1) AU4621799A (fr)
CA (1) CA2337048A1 (fr)
FR (1) FR2781160B1 (fr)
WO (1) WO2000001345A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2814958B1 (fr) * 2000-10-06 2003-03-07 Aventis Pasteur Composition vaccinale
WO2009039628A1 (fr) 2007-09-27 2009-04-02 Immunovaccine Technologies Inc. Utilisation de liposomes dans un véhicule composant une phase hydrophobe continue pour la délivrance de polynucléotides in vivo
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
BRPI0913612B8 (pt) * 2008-06-05 2021-05-25 Immunovaccine Technologies Inc composição injetável de vacina, método para obter a composição e uso da composição
EP2763698B1 (fr) 2011-10-06 2020-12-02 ImmunoVaccine Technologies Inc. Compositions liposomales comprenant un adjuvant qui active ou accroît l'activité de tlr2 et utilisations associées

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4240386A1 (en) * 1991-12-01 1993-06-17 Ko Jin Nam High purity, highly immunogenic hepatitis B vaccine - uses antigen isolated from human serum by affinity chromatography, induces antibodies in all subjects immunised
WO1995004523A1 (fr) * 1993-08-06 1995-02-16 Opperbas Holding B.V. Methode de preparation de vesicules chargees de structures biologiques, de biopolymeres et/ou d'oligomeres
WO1996014831A1 (fr) * 1994-11-14 1996-05-23 Pasteur Merieux Serums & Vaccins Adjuvant pour composition vaccinale
WO1996019237A1 (fr) * 1994-12-21 1996-06-27 Vacsyn S.A. Vaccin presentant une immunogenicite accrue
WO1996032102A1 (fr) * 1995-04-11 1996-10-17 Pasteur Merieux Serums Et Vaccins Utilisation d'un compose amphipathique cationique comme agent de transfection, comme adjuvant de vaccin, ou comme medicament
WO1998048836A1 (fr) * 1997-04-30 1998-11-05 Merieux Oravax Composition vaccinale anti-helicobacter comprenant un adjuvant de type th1

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5753262A (en) 1995-06-07 1998-05-19 Aronex Pharmaceuticals, Inc. Cationic lipid acid salt of 3beta N- (N', N'-dimethylaminoethane) - carbamoyl!cholestrol and halogenated solvent-free preliposomal lyophilate thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4240386A1 (en) * 1991-12-01 1993-06-17 Ko Jin Nam High purity, highly immunogenic hepatitis B vaccine - uses antigen isolated from human serum by affinity chromatography, induces antibodies in all subjects immunised
WO1995004523A1 (fr) * 1993-08-06 1995-02-16 Opperbas Holding B.V. Methode de preparation de vesicules chargees de structures biologiques, de biopolymeres et/ou d'oligomeres
WO1996014831A1 (fr) * 1994-11-14 1996-05-23 Pasteur Merieux Serums & Vaccins Adjuvant pour composition vaccinale
WO1996019237A1 (fr) * 1994-12-21 1996-06-27 Vacsyn S.A. Vaccin presentant une immunogenicite accrue
WO1996032102A1 (fr) * 1995-04-11 1996-10-17 Pasteur Merieux Serums Et Vaccins Utilisation d'un compose amphipathique cationique comme agent de transfection, comme adjuvant de vaccin, ou comme medicament
WO1998048836A1 (fr) * 1997-04-30 1998-11-05 Merieux Oravax Composition vaccinale anti-helicobacter comprenant un adjuvant de type th1

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
F. BRUNEL T AL.: "CATIONIC LIPID DC-CHOL INDUCES AN IMPROVED AND BALANCED IMMUNITY ABLE TO OVERCOME THE UNRESPONSIVENESS TO THE HEPATITIS B VACCINE.", VACCINE, vol. 17, no. 17, 23 April 1999 (1999-04-23), GUILDFORD, GB, pages 2192 - 2203, XP002126443 *

Also Published As

Publication number Publication date
FR2781160A1 (fr) 2000-01-21
CA2337048A1 (fr) 2000-01-13
WO2000001345A2 (fr) 2000-01-13
FR2781160B1 (fr) 2000-08-18
US6472159B1 (en) 2002-10-29
EP1093382A2 (fr) 2001-04-25
AU4621799A (en) 2000-01-24

Similar Documents

Publication Publication Date Title
WO2002013857A8 (fr) Vaccin comprenant au moins un antigene et un peptide antimicrobien a base de cathelicidine ou un derive de ce peptide
WO2002080965A3 (fr) Composition vaccinale
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
HUP0201653A2 (en) The use of thiazolidine-, oxazolidinedione derivatives for the preparation of pharmaceutical compositions improving ketosis
EP1955709A3 (fr) Compositions d'adjuvant d'amélioration des réponses immunitaires aux vaccins à base de polynucléotide
AU2002346973A1 (en) Oral Dosage Form for Propiverine or its Pharmaceutically Acceptable Salts with an Extended Release of the Active Ingredient
CA2237529A1 (fr) Compositions vaccinales pour administration intra-nasale comprenant du chitosane, et leur utilisation
EP0745387A3 (fr) Adjuvants pour vaccins viraux
WO2002009754A1 (fr) Nouveaux remedes contre le cancer
AU2002221519A1 (en) Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
AU4139801A (en) Controlled delivery of antigens
WO2001005355A3 (fr) Formulations d'il-11
WO2003014079A8 (fr) Polymorphe stable de flibanserine, procede de preparation associe et utilisation dudit polymorphe dans la preparation de medicaments
HK1063726A1 (en) Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
ZA200007548B (en) Matrix table enabling the prolonged release of trimetazidine after administration by the oral route.
EP2017269A3 (fr) Composition pharmaceutique comprenant forme cristalline II de Ritonavir et procédé de sa préparation
MY129437A (en) Drug formulation having controlled release of active compound
WO2002015959A3 (fr) Composes et compositions permettant de distribuer des agents actifs
AU3853495A (en) Immunogenic compositions
HUP0200527A2 (en) Use of antibodies for anticancer vaccination
AU2001258395A1 (en) Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
WO2000001345A3 (fr) Utilisation d'un compose amphipathique pour adjuver un vaccin sous-unitaire
IL236509A0 (en) Use of one or more HBV antigens for the preparation of oral pharmaceutical preparations for the treatment of a person with active HBV infection or hepatocellular carcinoma
WO2002053184A3 (fr) Utilisations de composes polycationiques
CA2452008A1 (fr) Ltb4 comme adjuvant de vaccin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2337048

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1999929389

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09720863

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999929389

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999929389

Country of ref document: EP